Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine

Carrie E Robertson, Ivan GarzaDepartment of Neurology, Mayo Clinic, Rochester, MN, USAAbstract: OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a novel preventive therapy for migraine headache. The data would support that it may be effective at reducing headache days in pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Robertson CE, Garza I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d61c8e60befc41f7829af236dcaf6094
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d61c8e60befc41f7829af236dcaf6094
record_format	dspace
spelling	oai:doaj.org-article:d61c8e60befc41f7829af236dcaf60942021-12-02T03:04:19ZCritical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine1176-63281178-2021https://doaj.org/article/d61c8e60befc41f7829af236dcaf60942012-01-01T00:00:00Zhttp://www.dovepress.com/critical-analysis-of-the-use-of-onabotulinumtoxina-botulinum-toxin-typ-a9052https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Carrie E Robertson, Ivan GarzaDepartment of Neurology, Mayo Clinic, Rochester, MN, USAAbstract: OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a novel preventive therapy for migraine headache. The data would support that it may be effective at reducing headache days in patients suffering from chronic migraine (&ge;15 headache days/month, with eight or more of those migraine headache days). The mechanism by which onabotulinumtoxinA exerts its effects on migraine is not yet understood. It is known to inhibit acetylcholine release at the neuromuscular junction, but this probably does not explain the observed antinociceptive properties noted in preclinical and clinical trials. This review will discuss the known mechanisms of action of botulinum toxin type A, and will review the available randomized, placebo-controlled trials that have looked at its efficacy as a migraine preventative. We also describe the onabotulinumtoxinA injection sites used at our institution.Keywords: botulinum toxin, prophylaxis, onabotulinumtoxinA, mechanism, migraine, preventionRobertson CEGarza IDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 35-48 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Robertson CE Garza I Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
description	Carrie E Robertson, Ivan GarzaDepartment of Neurology, Mayo Clinic, Rochester, MN, USAAbstract: OnabotulinumtoxinA, a neurotoxin, has been studied in numerous trials as a novel preventive therapy for migraine headache. The data would support that it may be effective at reducing headache days in patients suffering from chronic migraine (&ge;15 headache days/month, with eight or more of those migraine headache days). The mechanism by which onabotulinumtoxinA exerts its effects on migraine is not yet understood. It is known to inhibit acetylcholine release at the neuromuscular junction, but this probably does not explain the observed antinociceptive properties noted in preclinical and clinical trials. This review will discuss the known mechanisms of action of botulinum toxin type A, and will review the available randomized, placebo-controlled trials that have looked at its efficacy as a migraine preventative. We also describe the onabotulinumtoxinA injection sites used at our institution.Keywords: botulinum toxin, prophylaxis, onabotulinumtoxinA, mechanism, migraine, prevention
format	article
author	Robertson CE Garza I
author_facet	Robertson CE Garza I
author_sort	Robertson CE
title	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
title_short	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
title_full	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
title_fullStr	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
title_full_unstemmed	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
title_sort	critical analysis of the use of onabotulinumtoxina (botulinum toxin type a) in migraine
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/d61c8e60befc41f7829af236dcaf6094
work_keys_str_mv	AT robertsonce criticalanalysisoftheuseofonabotulinumtoxinabotulinumtoxintypeainmigraine AT garzai criticalanalysisoftheuseofonabotulinumtoxinabotulinumtoxintypeainmigraine
_version_	1718402010975305728

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine

Ejemplares similares